NCT02106351 - Efficacy And Safety Of Dysport In The Treatment Of Upper Limb Spasticity In Children | Biotech Hunter

Enrollment

212

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

September 21, 2017

Study Completion Date

September 4, 2018

Conditions

Upper Limb Spasticity (Altered Skeletal Muscle Performance) in Children

Interventions

BIOLOGICAL

Botulinum toxin type A

Subjects randomised to receive Dysport 2 U/kg, 8 U/kg or 16 U/kg administered intramuscularly in the study limb.

Trial Locations (31)

Unknown

Aurora

Washington D.C.

New Orleans

Royal Oak

Saint Paul

Omaha

Albuquerque

New York

Columbus

Portland

Austin

Dallas

Brussels

Brno

Prague

Beersheba

Jerusalem

Petah Tikva

Tel Aviv

Tel Litwinsky

La Paz

Celaya

Monterrey

Gdansk

Poznan

Wiązowna

Barcelona

Terrassa

Istanbul

Izmir

Kocaeli